191 related articles for article (PubMed ID: 33206027)
1. Sepsis target validation for repurposing and combining complement and immune checkpoint inhibition therapeutics.
Rodrigues PRS; Picco N; Morgan BP; Ghazal P
Expert Opin Drug Discov; 2021 May; 16(5):537-551. PubMed ID: 33206027
[No Abstract] [Full Text] [Related]
2. Complement in sepsis-when science meets clinics.
Mollnes TE; Huber-Lang M
FEBS Lett; 2020 Aug; 594(16):2621-2632. PubMed ID: 32621378
[TBL] [Abstract][Full Text] [Related]
3. A New Method for Optimizing Sepsis Therapy by Nivolumab and Meropenem Combination: Importance of Early Intervention and CTL Reinvigoration Rate as a Response Marker.
Gillis A; Ben Yaacov A; Agur Z
Front Immunol; 2021; 12():616881. PubMed ID: 33732241
[No Abstract] [Full Text] [Related]
4. Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma.
Chan LL; Chan SL
Expert Opin Emerg Drugs; 2021 Mar; 26(1):39-52. PubMed ID: 33724135
[TBL] [Abstract][Full Text] [Related]
5. Complexity of complement activation in sepsis.
Markiewski MM; DeAngelis RA; Lambris JD
J Cell Mol Med; 2008 Dec; 12(6A):2245-54. PubMed ID: 18798865
[TBL] [Abstract][Full Text] [Related]
6. Complement C5a Receptor 1 Exacerbates the Pathophysiology of
Herrmann JB; Muenstermann M; Strobel L; Schubert-Unkmeir A; Woodruff TM; Gray-Owen SD; Klos A; Johswich KO
mBio; 2018 Jan; 9(1):. PubMed ID: 29362231
[TBL] [Abstract][Full Text] [Related]
7. Controlling the complement system in inflammation.
Kirschfink M
Immunopharmacology; 1997 Dec; 38(1-2):51-62. PubMed ID: 9476114
[TBL] [Abstract][Full Text] [Related]
8. Complement-induced impairment of the innate immune system during sepsis.
Albrecht EA; Ward PA
Curr Allergy Asthma Rep; 2004 Sep; 4(5):359-64. PubMed ID: 15283874
[TBL] [Abstract][Full Text] [Related]
9. Buena VISTA: a promising outlook on targeting immune checkpoint regulators to combat sepsis.
Mott MD; Trusiano B; Allen IC
J Leukoc Biol; 2024 May; 115(6):1002-1004. PubMed ID: 38526166
[No Abstract] [Full Text] [Related]
10. Immune Deregulation in Sepsis and Septic Shock: Reversing Immune Paralysis by Targeting PD-1/PD-L1 Pathway.
Nakamori Y; Park EJ; Shimaoka M
Front Immunol; 2020; 11():624279. PubMed ID: 33679715
[TBL] [Abstract][Full Text] [Related]
11. Emerging immune checkpoint inhibitors for the treatment of head and neck cancers.
Green SE; McCusker MG; Mehra R
Expert Opin Emerg Drugs; 2020 Dec; 25(4):501-514. PubMed ID: 33196319
[No Abstract] [Full Text] [Related]
12. Towards personalized medicine: a scoping review of immunotherapy in sepsis.
Slim MA; van Mourik N; Bakkerus L; Fuller K; Acharya L; Giannidis T; Dionne JC; Oczkowski SJW; Netea MG; Pickkers P; Giamarellos-Bourboulis EJ; Müller MCA; van der Poll T; Wiersinga WJ; ; Vlaar APJ; van Vught LA
Crit Care; 2024 May; 28(1):183. PubMed ID: 38807151
[TBL] [Abstract][Full Text] [Related]
13. Anaphylatoxins: their role in bacterial infection and inflammation.
Haas PJ; van Strijp J
Immunol Res; 2007; 37(3):161-75. PubMed ID: 17873401
[TBL] [Abstract][Full Text] [Related]
14. Host innate immune responses to microbial pathogens.
Delaloye J; Calandra T
Curr Vasc Pharmacol; 2013 Mar; 11(2):123-32. PubMed ID: 23506491
[TBL] [Abstract][Full Text] [Related]
15. Editorial: The Role of Complement in Tumors.
Rolfe BE; Pio R; Woodruff TM; Markiewski MM; Manthey HD
Front Immunol; 2020; 11():139. PubMed ID: 32117286
[No Abstract] [Full Text] [Related]
16. Emerging therapeutic targets for sepsis.
Tindal EW; Armstead BE; Monaghan SF; Heffernan DS; Ayala A
Expert Opin Ther Targets; 2021 Mar; 25(3):175-189. PubMed ID: 33641552
[No Abstract] [Full Text] [Related]
17. Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver.
Hewitt DB; Rahnemai-Azar AA; Pawlik TM
Expert Opin Investig Drugs; 2021 Aug; 30(8):827-835. PubMed ID: 34102935
[No Abstract] [Full Text] [Related]
18. Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression.
Patil NK; Bohannon JK; Sherwood ER
Pharmacol Res; 2016 Sep; 111():688-702. PubMed ID: 27468649
[TBL] [Abstract][Full Text] [Related]
19. Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
Apostolidis J; Sayyed A; Darweesh M; Kaloyannidis P; Al Hashmi H
J Immunol Res; 2020; 2020():9350272. PubMed ID: 33178841
[TBL] [Abstract][Full Text] [Related]
20. Alleviation of exhaustion-induced immunosuppression and sepsis by immune checkpoint blockers sequentially administered with antibiotics-analysis of a new mathematical model.
Gillis A; Beil M; Halevi-Tobias K; van Heerden PV; Sviri S; Agur Z
Intensive Care Med Exp; 2019 Jun; 7(1):32. PubMed ID: 31187301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
